Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.08. Core earnings rose 4% year over year on a reported ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

(Reuters) - GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts and dual sourcing for its medicines, but offered few details. The ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

GSK GSK1.36%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug ...